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The Thomsen-Friedenreich Antigen-Binding Lectin
Jacalin Interacts with Desmoglein-1 and Abrogates
the Pathogenicity of Pemphigus Foliaceus
Autoantibodies In Vivo
Ning Li1, Moonhee Park1, Minglang Zhao1, Julio Hilario-Vargas1, David M. McInnes1, Phillip S. Prisayanh1,
Zhi Liu1,2 and Luis A. Diaz1
Pemphigus foliaceus (PF) is an autoimmune skin blistering disease mediated by pathogenic autoantibodies
against the desmosomal core glycoprotein desmoglein-1 (Dsg1). This study demonstrated that the O-glycan-
specific plant lectin jacalin binds Dsg1 and inhibits the interaction of Dsg1/PF IgG. N-glycosylation is not
involved in the interaction of Dsg1/jacalin or Dsg1/PF IgG. Subcutaneous injection of jacalin into neonatal mice
drastically reduced PF IgG deposition at the epidermal cell surface and blocked PF IgG-induced skin blisters,
both clinically and histologically. Interestingly, another plant lectin, peanut agglutinin, which shares the same
carbohydrate specificity toward the O-linked carbohydrate structure known as Thomsen-Friedenreich antigen
(TF antigen, Galb1-3GalNAca-O-Ser/Thr), also bound Dsg1 and blocked the skin blistering. In contrast, the plant
lectin vicia villosa-B4 (VVL-B4), which shares the carbohydrate specificity toward the O-linked monosaccharide
known as Thomsen-nouveau antigen (GalNAc-a1-O-Ser/Thr), did not bind Dsg1 and did not show a protective
effect against the disease induced by the autoantibodies. Collectively, these results suggest that the binding of
jacalin to O-linked TF carbohydrate motifs on Dsg1 impairs the Dsg1/PF autoantibody interactions and
abrogates its pathogenicity in vivo. TF-specific binding ligands may have a potential therapeutic value for PF.
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INTRODUCTION
The endemic and nonendemic forms of pemphigus foliaceus
(PF) are autoimmune blistering skin diseases characterized by
superficial blisters, epidermal cell detachment (known as
acantholysis) at the level of the granular layer of the
epidermis, and IgG autoantibodies bound to the surface of
detached keratinocytes (Lever et al., 1953; Beutner et al.,
1968). The nonendemic form of PF occurs sporadically in
many regions of the world and the endemic form, also known
as Fogo Selvagem (FS), is common in certain rural areas of
Brazil (Aoki et al., 2004).
The antiepidermal autoantibodies in both clinical forms of
PF are predominantly and in a pathogenic manner IgG4
subclass, as demonstrated by passive transfer of the IgG
fraction of these sera into mice (Rock et al., 1989; Futei et al.,
2001). Neonatal mice that are injected with PF IgG, IgG4, or
Fab’ monovalent fragment develop skin blisters and sub-
corneal vesicles, which recapitulate the clinical and histo-
logical features of the human disease in these animals
(Roscoe et al., 1985; Rock et al., 1989, 1990; Espana et al.,
1997). The antigen targeted by pathogenic PF autoantibodies
is desmoglein-1 (Dsg1), a desmosomal core glycoprotein
expressed predominantly in the upper layers of the epidermis
(Koulu et al., 1984; Rappersberger et al., 1992). Affinity-
purified anti-Dsg1 autoantibodies from PF sera are able to
induce epidermal blisters and subcorneal acantholysis in
mice passively transferred with these fractions (Amagai et al.,
1995a; Arteaga et al., 2002).
In spite of the remarkable advances in understanding the
molecular mechanisms of autoantibody-induced acantholysis
in pemphigus (Rubenstein and Diaz, 2006; Kitajima and
Aoyama, 2007; Sharma et al., 2007; Culton et al., 2008;
Waschke, 2008), these knowledge has not been translated
into newer therapies of patients. Current therapy of PF
patients mainly relies on the use of corticosteroids and
immunosuppressive agents. Although these therapies signifi-
cantly reduce the mortality of the disease, they result in
significant morbidity because of side effects.
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Identifying means of interfering with the autoantibody–-
antigen interaction may represent an alternative approach to
treat autoantibody-mediated autoimmune diseases. While
investigating a possible case of IgA pemphigus, we noticed
that jacalin-agarose, which was used to precipitate IgA, also
precipitated the baculovirus-expressed recombinant Dsg1
ectodomain (rDsg1). Further studies demonstrate that binding
of jacalin interferes with PF autoantibody binding and
protects mice against PF IgG-induced skin blisters.
RESULTS
Jacalin binds Dsg1
Aliquots of conditioned culture medium containing baculo-
virus-expressed human rDsg1 were incubated with agarose
beads that were conjugated with jacalin or protein G/A
(negative control). Following extensive wash (see Materials
and Methods), bound proteins were released by boiling in
SDS sample buffer and subjected to immunoblotting (IB). As
shown in Figure 1a, jacalin-agarose (lane 1), but not protein
G/A-agarose (lane 2), was able to pull-down Dsg1. To
demonstrate the carbohydrate-dependency of the binding, we
tested the ability of jacalin-specific sugars to elute the bound
Dsg1. We found that both melibiose (0.1M) and D-galactose
(0.8M) were able to elute the bound Dsg1 (lanes 3 and 4).
Moreover, preincubation of jacalin-agarose with D-galactose
diminished its binding to Dsg1 (lane 5) as compared with those
preincubated with tris-buffered saline (TBS)-Ca2þ buffer alone
(lane 6). These results demonstrate that jacalin is able to bind
rDsg1 and that the binding is galactose-dependent.
Considering possible differences in glycosylation of proteins
expressed by insect cells and mammalian epidermal keratino-
cytes, we examined the interaction of jacalin with Dsg1
extracted from the skin. Tissue lysates from human epidermis
and mouse skin were incubated with jacalin-agarose or protein
G/A-agarose beads. Proteins bound by the beads were released
and analyzed by IB using antibodies to Dsg1. As shown in
Figure 1b, the 160-kDa Dsg1 from mouse or human epidermal
extracts was precipitated by jacalin-beads (lanes 1 and 2), but
not by protein G/A-beads (lanes 3 and 4).
Jacalin blocks the binding of PF autoantibodies to Dsg1
Finding that jacalin interacts with the ectodomain of Dsg1
prompted us to investigate whether such interaction could
interfere with the binding of PF autoantibodies to Dsg1. We
tested this possibility by ELISA and immunoprecipitation (IP)
assays using a test FS serum (PF-1). ELISA results showed a
concentration-dependent inhibition of jacalin on the binding
of FS autoantibodies (Figure 2a), and that the inhibition was
reversible by D-galactose (Figure 2b). A similar dose-dependent
blocking effect on the binding of Dsg1 to FS autoantibodies
was also observed by IP analysis (Figure 2c). To assess whether
the jacalin inhibition on FS autoantibody binding is applicable
to other FS/PF sera, we tested additional samples. Represen-
tative IP data are shown in Figure 2d. Among 20 PF/FS
sera tested, jacalin significantly reduced Dsg1 binding in
18 samples (90%), and in 2 sera the reduction was modest
(one of such sera, PF-2, is shown in lanes 15 and 16).
Interaction of Dsg1/jacalin and Dsg1/PF autoantibodies
is N-glycosylation-independent
Although jacalin is a well-known O-glycan-specific plant
lectin (Hortin, 1990; Tachibana et al., 2006), a few studies
have suggested that jacalin may also have affinity for N-
glycan (Do and Lee, 1998; Bourne et al., 2002). To evaluate
whether jacalin binds to N-glycans on Dsg1, we produced
the Dsg1 in High-Five cells in the presence of tunicamycin to
inhibit N-glycosylations. As expected, Dsg1 expressed in the
presence of tunicamycin showed a reduced molecular weight
on SDS–PAGE (Figure 3a, lane 1 vs. lane 2), an indication of
N-glycosylation inhibition. We then used the same amount
of tunicamycin-treated and nontreated Dsg1 for lectin
pull-down assay. As expected, immobilized concanavalin
A reacted poorly with tunicamycin-treated Dsg1 (Figure 3a,
lanes 3 vs. 4), a further indication of the N-glycosylation
inhibition. In contrast, immobilized jacalin was able to
precipitate both the tunicamycin-treated and nontreated
Dsg1 (Figure 3a, lanes 5 vs. 6). This result demonstrates that
N-glycans on Dsg1 are not involved in jacalin binding.
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Figure 1. Jacalin (Jac) binds desmoglein-1 (Dsg1). (a) Binding to recombinant
Dsg1 ectodomain (rDsg1). rDsg1 was incubated with Jac-agarose (lanes 1,
3–6) or protein G/A-agarose beads (lane 2). Bound-Dsg1 was released by
boiling in SDS sample buffer (lanes 1–2 and 5–6) or eluted with Jac-inhibiting
sugars (lane 3: 0.1 M melibiose; lane 4: 0.8 M D-galactose). In one set of
experiments, Jac beads were preincubated with 0.8M D-galactose (lane 5) or
buffer (lane 6) before adding the pemphigus foliaceus serum to further show
the sugar-dependency binding. Released Dsg1 was analyzed by
immunoblotting (IB) using anti-histidine antibodies. (b) Binding to epidermal
Dsg1. Tissue lysates from human (H) or mouse (M) epidermis were incubated
with Jac-agarose (lanes 1 and 2) or protein G/A-agarose beads (lanes 3 and 4)
followed by IB using anti-Dsg1 antibodies.
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We also examined the binding ability of tunicamycin-
treated Dsg1 with PF autoantibodies, as the role of
N-glycosylation of Dsg1 in PF autoantibody binding has
been controversial (Olague-Alcala and Diaz, 1993; Amagai
et al., 1995b; Ortiz-Urda et al., 2003). We tested 12 PF/FS
sera (6 PF and 6 FS) by IP, and all reacted well with both
tunicamycin-treated and nontreated Dsg1. Representative IP
data are shown in Figure 3b.
Jacalin binds the epidermis and inhibits PF autoantibodies binding
We next examined the binding of jacalin to cryostat sections
of human and murine skin by immunofluorescence techni-
ques. Sections of human or mouse skin incubated with FITC-
conjugated jacalin produced a ‘‘pemphigus-like’’ staining
pattern (Supplementary Figure S1-A online). Preincubation of
the human or mouse skin sections with jacalin significantly
inhibited PF IgG binding to the epidermis (Supplementary
Figure S1-B, panels b and d online) as compared with those
preincubated with TBS-Ca2þ buffer alone (Supplementary
Figure S1-B, panels a and c online).
Jacalin abrogates the pathogenicity of PF autoantibodies in mice
We further investigated the in vivo effect of jacalin in the PF
mouse model using pathogenic IgG isolated from PF-1, a
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Figure 2. Jacalin (Jac) inhibits pemphigus foliaceus (PF) autoantibody binding to desmoglein-1 (Dsg1). (a) ELISA assay showing dose-dependent inhibitory
effect of Jac. Dsg1-coated microplates were preincubated with Jac (100, 250, and 500mgml1) followed by incubating with PF-1 serum. Cutoff value: 0.421.
(b) Reverse effects of D-galactose on Jac inhibition. Recombinant Dsg1 ectodomain (Dsg1)-microplates were preincubated with tris-buffered saline-Ca2þ buffer
(left column), Jac (100mgml1) (center), or Jac (100 mgml1) plus D-galactose (0.8 M) (right) before adding PF-1 serum. (n¼3, *Po0.05 (Student’s t-test)).
(c) Immunoprecipitation (IP) results showing dose-dependent inhibitory effect of Jac. rDsg1 was preincubated with Jac (0, 10, and 100 mgml1) before IP.
(d) Representative IP showing that 100 mgml1 of Jac (even-numbered lanes) inhibits the interaction of rDsg1 with eight PF/Fogo Selvagem sera compared with
the controls that were preincubated with buffer (odd-numbered lanes).
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Figure 3. N-glycosylation is not involved in desmoglein-1 (Dsg1)/jacalin
(Jac) and Dsg1/pemphigus foliaceus (PF) IgG binding. Baculovirus expressed
Dsg1 ectodomain produced in the presence or absence of tunicamycin
(0.5mgml1) was used for the experiments. (a) Immunoblotting shows that
tunicamycin treatment reduced the molecular weight of Dsg1 (untreated in
lane 1 vs. treated in lane 2). Concanavalin A (ConA)-beads precipitated poorly
with Dsg1 produced in the presence of tunicamycin (lanes 3) compared with
nontreated Dsg1 (lane 4). In contrast, Jac-agarose precipitated both the
tunicamycin-treated (lane 6) and nontreated Dsg1 (lane 5). (b) Representative
immunoprecipitation shows that five PF/Fogo Selvagem sera reacted with
tunicamycin-treated Dsg1 (even-numbered lanes) as well as nontreated Dsg1
(odd-numbered lanes).
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serum that was significantly inhibited by jacalin (see Figure 2a–c).
Control mice (n¼ 4) pretreated with vehicle alone developed
blisters, clinically and histologically (Figure 4aA and B)
20 hours after PF IgG injections. In contrast, mice pretreated
with jacalin (80 mg g1 body weight, n¼4; 160mg g1 body
weight, n¼4) did not develop skin lesions (Figure 4aD and E).
Direct immunofluorescence staining revealed a significant
reduction of IgG binding to the epiderms in jacalin-treated
mice (Figure 4aF) compared with those of control mice
(Figure 4aC). The inhibition of jacalin on the induction of skin
lesions in mice was dose dependent (Figure 4b). These results
suggest that jacalin affects the in vivo binding of PF
autoantibodies to the epidermis and thus inhibits disease.
Study of other plant lectins
Jacalin is known to have binding specificities for theO-linked
disaccharide Thomsen-Friedenreich antigen (TF antigen,
Galb1-3GalNAc-a1-O-Ser/Thr) and the monosaccharide
Thomsen-nouveau antigen (Tn antigen, GalNAc-a1-O-Ser/
Thr) in either the asialylated or sialylated form. It is known
that other lectins have overlapping and distinct binding
specificities as jacalin. For example, the peanut agglutinin
(PNA) has binding affinity for TF antigen in its asialylated
form only, whereas vicia villosa-B4 (VVL-B4) binds specifi-
cally to Tn antigen. Therefore, we tested the reactivity of
these two lectins with Dsg1 by the lectin pull-down assay.
The results showed that PNA, but not VVL-B4, interacted with
the epidermal Dsg1 extracted from human or mouse skin
(Figure 5a), suggesting that Dsg1 carries the asialylated form
of TF antigen but not the Tn antigen. Moreover, preinjection
of PNA (80mg g1 body weight, n¼9) abrogated the
pathogenicity of PF IgG, whereas preinjection of the same
dose of VVL-B4 (n¼ 3) did not show any blocking effect
(Figure 5b). Similar to jacalin, subcutaneous (s.c.) injection of
PNA or VVL-B4 alone did not cause any abnormal
appearance of the mouse skin. Table 1 summarizes the
binding specificity of the lectins tested and their effect on PF
IgG-induced skin blisters in mice.
Effect of jacalin on the pathogenicity of an additional PF serum
that showed a modest reduction in Dsg1 binding by jacalin
As described above, two patients’ sera, including PF-2,
showed a modest reduction on the binding of Dsg1 by IP
when preincubated with jacalin. We expected that jacalin
would have a lesser inhibitory effect on the pathogenicity of
these PF autoantibodies. We tested this hypothesis in mice
using pathogenic IgG prepared from PF-2 serum. Out of six
animals preinjected with jacalin, five developed skin blisters,
but the disease score was significantly reduced (Po0.01,
Student’s t-test) compared with those pretreated with vehicle
(Table 1).
DISCUSSION
Jacalin is a plant lectin that is highly specific for the a-O-
glycoside of the terminal disaccharide TF carbohydrate motif
(asialylated or sialylated) and its monosaccharide precursor
Tn antigen (Mahanta et al., 1990; Kabir, 1998; Tachibana
et al., 2006). Immobilized jacalin is often used for isolation of
IgA1 from human serum and purifying other O-glycosylated
proteins (Roque-Barreira and Campos-Neto, 1985; Hortin,
1990). In this study, we found that jacalin-agarose beads
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Figure 4. Jacalin (Jac) protects mice from developing pemphigus foliaceus
(PF). (a) Representative results showing that mice preinjected with control
buffer (n¼ 4) developed clinical and histological blisters upon injection with
IgG from PF-1 (A, B). In contrast, mice pretreated with Jac (80 mg g1 body
weight, n¼4; 160 mg g1 body weight, n¼4) did not develop skin blisters
clinically and histologically (D, E). Direct immunofluorescence staining
showed a significant reduction of IgG binding to the epidermis in mice treated
with Jac (F) compared with buffer-treated controls (C). Bars¼ 100mm (B, E)
and 10 mm (C, F), respectively. (b) Jac inhibits PF blistering in a dose-
dependent manner. Animals were pretreated (s.c.) with different doses of Jac
and then injected (s.c.) with the same dose of pathogenic PF IgG. Clinical
disease was scored for each group of experimental mice. (n¼4; *Po0.05,
**Po0.01 (Student’s t-test).)
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precipitated the rDsg1 (Figure 1a) as well as the native Dsg1
from human and mouse epidermal lysates (Figure 1b). We
demonstrated that the binding between jacalin and Dsg1 is
galactose-dependent ((Figure 1a), but N-glycosylation-
independent (Figure 3a), supporting the notion that jacalin
has no or extremely low affinity for N-glycans (Hortin and
Trimpe, 1990; Arockia Jeyaprakash et al., 2005). Although
Dsg1 is known to be N-glycosylated (Koch et al., 1991;
Olague-Alcala and Diaz, 1993; Amagai et al., 1995b; Ortiz-
Urda et al., 2003), its possible modification by O-linked
oligosaccharides is less defined. The observation that Dsg1
interacts with jacalin and PNA but not VVL-B4 (Figure 5a)
indicates that Dsg1 carries O-linked disaccharide TF antigen
(asialylated) but not the monosaccharide Tn antigen.
By competition ELISA and IP, we showed that jacalin was
able to inhibit the binding of PF autoantibodies to Dsg1 in
concentration- and galactose-dependent manners (Figure
2a–c). A significant inhibitory effect was observed in the
majority of patients’ sera tested (90%, n¼ 20, Figure 2d)
including PF-1, which was used throughout the study. Jacalin
also markedly inhibited the binding of PF autoantibodies to
human and mouse epidermis (Supplementary Figure S1
online). Furthermore, preinjection (s.c.) of jacalin into mice
diminished the in vivo binding of PF-1 autoantibody to the
epidermis and blocked skin disease (Figure 4). Interestingly,
injection (s.c.) of jacalin alone did not cause any abnormal
effect on mouse skin (data not shown), suggesting that
binding of jacalin does not impair the adhesive function of
Dsg1. Another lectin PNA, which shares the same carbo-
hydrate specificity for the O-linked asialylated TF antigen but
not the sialylated form, interacted with Dsg1 and blocked
PF-1 autoantibody-induced skin blisters in mice (Figure 5). In
contrast, lectin VVL-B4, which shares the carbohydrate
specificity for the O-linked Tn antigen, did not interact with
Dsg1 and did not show any beneficial effect on the disease
induced by PF-1 IgG (Figure 5). These data suggest that
binding of the O-linked TF carbohydrate motif of Dsg1 by
jacalin and PNA can abrogate the pathogenicity of PF
autoantibodies. However, there are a few PF sera (2 out of
20), in which the Dsg1–PF autoantibody interaction was
modestly inhibited by jacalin, and the in vivo protective
effect of jacalin on disease was less effective as demonstrated
with PF-2 serum (Table 1).
The molecular mechanism involved in the inhibitory
effects of jacalin on PF autoantibody binding to Dsg1 is
not clear. It is known that pathogenic PF autoantibodies
bind calcium-dependent conformational epitopes located
in the NH2-terminal region (EC1-2 or 1-161 residues) of
Dsg1 (Eyre and Stanley, 1987; Kowalczyk et al., 1995;
Sekiguchi et al., 2001; Li et al., 2003). These epitopes are
unlikely to be composed of the carbohydrate moieties as the
bacterial-expressed Dsg1 ectodomain, which had no glyco-
sylation modifications, was still recognized by PF sera
(Dmochowski et al., 1994). It is possible that jacalin
binds the TF carbohydrate motifs of Dsg1 and spatially
masks the major epitopes recognized by PF autoantibodies,
thereby inhibiting the subsequent binding of PF autoanti-
bodies. Alternatively, the binding of jacalin to Dsg1 may
induce conformational changes of Dsg1, which impairs its
interaction with PF autoantibodies. Identification of the
position of the O-glycosylation sites on Dsg1 may help
to understand the mechanism of action of jacalin. Potential
O-glycosylation sites are predicted to be located in the
membrane-proximal EC5 domain and possibly in other
domains (EC1-4), depending on which predicting programs/
methods are used (http://www.turing.cs.iastate.edu/EnsembleGly;
Human Mouse
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Figure 5. Peanut agglutinin (PNA), but not vicia villosa-B4 (VVL-B4), binds
to Dsg1 and abolishes the pathogenicity of PF autoantibodies. (a) Lectin
pull-down assay. Tissue lysates from human epidermis (lanes 1 and 2) or
mouse skin (lanes 3 and 4) were incubated with PNA-agarose (lanes 1 and 3)
or VVL-B4-agarose beads (lanes 2 and 4). Dsg1 was detected by
immunoblotting using anti-Dsg1 antibodies. PNA but not VVL-B4 was able to
pull-down the epidermal Dsg1. (b) IgG passive transfer. Neonatal mice
pretreated with PNA (160 mg g1 body weight, n¼ 9) or VVL-B4 (160mg g1
body weight, n¼ 3), followed by subcutaneous injection of pathogenic IgG
from PF-1. Injected mice were examined 20hours after IgG injection. PNA (A
and B), but not VVL-B4 (C and D), inhibits PF IgG-induced skin blisters in
mice. Bar¼50 mm.
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http://www.cbs.dtu.dk/services/netoglyc; http://www.comp.chem.
nottingham.ac.uk/glyco). Further experimental determination of
the O-glycosylation sites on Dsg1 may shed light into the
inhibitory mechanism.
Two putative N-glycosylation sites (residues 61 and 131)
are identified within the NH2-terminal region of Dsg1, where
PF autoantibodies bind. The influence of the N-lined
glycosylation on PF autoantibody binding has been examined
with conflicting results reported. Although earlier studies
showed that the binding of PF autoantibodies to Dsg1 is
N-glycosylation-independent (Olague-Alcala and Diaz,
1993; Amagai et al., 1995b), a recent study by Ortiz-Urda
et al. (2003) suggested that most PF epitopes are determined
by N-linked carbohydrates. Ortiz-Urda et al. (2003) further
showed that topically applied lectin wheat germ agglutinin,
which binds the N-linked carbohydrates, was able to block
most PF autoantibody binding to the epidermis and abrogated
their pathogenicity in mice (Ortiz-Urda et al., 2003).
In contrast to the results by Ortiz-Urda et al. (2003), our IP
data show that inhibition of N-glycosylation of Dsg1 by
tunicamycin does not attenuate their binding to PF/FS sera
(n¼12) (Figure 3b). Our results support the notion that
binding of PF IgG to Dsg1 is N-glycosylation-independent
(Olague-Alcala and Diaz, 1993; Amagai et al., 1995b). It
should be noted that the conclusion of N-glycosylation-
dependent PF autoantibody binding was mainly based on the
observation that, by IB, the majority of PF sera (7 out of 12
sera tested) failed to react with human epidermal Dsg1 that
has been digested with PNGase F (Ortiz-Urda et al., 2003).
However, it is known that IB analysis is not an optimal
technique to reveal the binding of PF autoantibodies to Dsg1
because more than half of PF sera failed to react with Dsg1 by
this technique, presumably due to the loss of the conforma-
tional epitopes under the denatured conditions inherent to IB
(Eyre and Stanley, 1987; Hashimoto et al., 1990; Kowalczyk
et al., 1995; Amagai et al., 1995a). It is probable that the
failure of recognizing Dsg1 by most of the PF sera in the study
by Ortiz-Urda et al. (2003) was due to the limited sensitivity
of the IB analysis rather than the removal of N-linked
carbohydrates. Furthermore, we could not confirm that wheat
germ agglutinin was capable of blocking PF IgG-induced skin
blistering in mice. Instead of a beneficial effect, we found
that wheat germ agglutinin itself induces intraepidermal
cell detachment (acantholysis-like) and skin blisters upon
injection into mice (unpublished observation). The reason for
this conflicting observation is not clear and requires further
investigation.
The TF disaccharide (a-anomer, asialylated), recognized
both by jacalin and PNA, is a tumor-associated carbohydrate
structure. This glycotope occurs on the cell surface of a few
normal epithelial cells, but is overexpressed on many types of
carcinomas as a result of incomplete O-glycosylation of cell
membrane proteins (Springer, 1984; Cao et al., 1996). Its
cryptic form (sialylated TF), which interacts with jacalin but
not PNA, is expressed on many normal tissues/organs
including blood cells (Cao et al., 1996; Kabir, 1998). The
b-anomer of TF (Galb1-3GalNAc-b), found in the termini of
certain glycolipids such as GM1 ganglioside and asialo-GM1
ganglioside (Rittenhouse-Olson, 2007), may interact with
PNA but not jacalin. Although jacalin and PNA are dietary
lectins that can be eaten raw, and local administration of the
two lectins into neonatal mice did not induce any obvious
toxicity within 24 hours duration, it is possible that systemic
administration of these lectins, especially jacalin, may be
toxic/harmful because of its agglutinating properties of
erythrocytes and its mitogenicity for human CD4þ T cells
(Cao et al., 1996; Kabir, 1998). Our findings, however, may
lead to a new therapeutic strategy for PF, that is, targeting the
TF glycotope with other more specific TF-binding ligands,
such as anti-TF antibodies (Heimburg et al., 2006) or peptides
(Landon et al., 2004). These agents react only with the
asialylated a-anomer TF disaccharide, but not with its more
common cryptic form (sialylated TF) that are expressed on
cell surface of many normal cells including erythrocytes.
Further studies are required to test the potential therapeutic
value of the TF-specific agents for PF.
Table 1. In vivo effect of plant lectins in IgG passive transfer mouse model of PF
IgG Treatment Oligosaccharide specificity
No. of mice
tested
No. of mice
with skin blister
No. of mice without
skin blister
PF-1 Vehicle 15 15 0
Jacalin Galb1-3GalNAc-a (asialo or sialo); GalNAc 8 0 8
PNA Galb1-3GalNAc-a or –b (asialo) 9 11 8
VVL-B4 GalNAc 3 3 0
PF-2 Vehicle 6 6 0
Jacalin 6 52 1
Abbreviations: Gal, galactose; GalNAc, N-acetylglactosamine; Glc, glucose; PF, pemphigus foliaceus; PNA, peanut agglutinin; s.c., subcutaneous; TBS, tris-
buffered saline; VVL-B4, vicia villosa-B4 lectin.
Neonatal mice were preinjected (s.c.) with vehicle (TBS-Ca2+) or lectins for 2 hours followed by pathogenic PF IgG injection (s.c.). Pathogenic IgG from two
patients’ sera was used. PF-1 serum showed a remarkable inhibition in Dsg1 binding by jacalin, whereas PF-2 showed a marginal reduction in Dsg1 binding
by jacalin. Animals were evaluated 20 hours after PF IgG injection. Jacalin: 80–160mg g-1 body weight; PNA and VVL-B4: 160mg g1 body weight.
1Minimum disease score (0.5+).
2Overall lower disease score (1.25+0.36) compared with those preinjected with vehicle (2.58+0.20) (Po0.01, Student’s t-test).
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MATERIALS AND METHODS
Patient sera
Sera from 20 PF/FS patients (11 PF sera from the United States and 9
FS sera from Brazil) were included in this study. A well-characterized
FS serum (PF-1), which was available in a relatively large quantity,
was used throughout this study. A second PF serum (PF-2) that
showed a modest reduction in Dsg1 binding by jacalin was also used
for IgG passive transfer experiments (Table 1). The diagnosis of PF/FS
had previously been confirmed using established clinical, histologi-
cal, and serological criteria. This study was approved by the
Institutional Review Board at UNC.
Plant lectins
Jacalin (Artocarpus integrifolia agglutinin), PNA, VVL-B4, concana-
valin A, PNA-agarose, and VVL-B4-agarose were purchased from
Sigma (St Louis, MO). Agarose-bound jacalin was from ICN
Pharmaceuticals (Irvine, CA). Concanavalin A-sepharose was from
Amersham Phamacia Biotech (Piscataway, NJ). FITC-conjugated
jacalin was purchased from Vector Laboratories (Burlingame, CA).
Production of rDsg1
The ectodomain of human Dsg1 with a carboxyl-terminal histidine
tag was produced in a baculovirus expression system as described
previously (Li et al., 2003). To produce Dsg1 without N-glycosyla-
tion, we expressed Dsg1 in High-Five cells in the presence of
tunicamycin (0.5 mgml1) as described by Amagai et al. (1995b). For
ELISA, Dsg1 was purified by nickel affinity chromatography as
described previously (Ding et al., 1999).
Lectin pull-down assay
Conditioned culture medium containing rDsg1 or skin/epidermal
lysates were incubated with immobilized lectins for 1.5 hours at
4 1C. Negative control experiments were carried out using agarose
beads conjugated with protein G/A. After centrifugation, the beads were
washed three times for 10minutes, each with either of the following
buffers: (a) 0.1% Triton X-100 in TBS-Ca2þ (10mM Tris-HCl, pH 7.4,
140mM NaCl, and 5mM CaCl2), (b) RIPA buffer (1% NP40, 0.25%
sodium deoxycholate, 0.1% SDS, 50mM Tris-HCl, pH 7.4, and 150mM
NaCl), or (c) high ionic buffer (100mM Tris-HCl, pH 7.4, and 500mM
NaCl). Proteins bound to the beads were released by boiling in 2 SDS
sample buffer or eluted with 0.8M D-galactose or 0.1M melibiose. The
eluates were fractioned by SDS–PAGE and then subjected to IB using
anti-histidine or anti-Dsg1 antibodies (Emery et al., 1995).
ELISA
Dsg1-ELISA was performed as previously reported (Warren et al.,
2000) with the following modifications. Various amounts of jacalin
in TBS-Ca2þ buffer containing 0.2% BSA and 0.05% Tween 20 were
added in duplicate to the wells. In some experiments, jacalin was
preincubated with 0.8 M D-galactose before adding to the plates.
Following a 1-hour incubation at room temperature, the plate was
washed five times with TBS-Ca2þ buffer (pH 7.2) containing 0.05%
Tween 20. The plate was then subjected to ELISA assay using PF
serum samples (1:200).
IP
Cold IP was performed as previously described (Li et al., 2003). In
brief, aliquots of conditioned culture supernatant containing the
histidine-tagged rDsg1 were preincubated with buffer or jacalin and
then incubated with PF serum (1:200). The mixture was then
subjected to IP, followed by IB using horseradish peroxidase-
conjugated anti-histidine antibodies.
Induction of experimental PF and testing the effect of plant
lectins
Neonatal BALB/c mice (1–2 days old) were used for experimental PF
induction (Anhalt et al., 1982; Rock et al., 1989). Animal care/
experiments were approved by the Animal Care Committee at the
institute and were in accordance with NIH guidelines. To test the
effect of lectins, animals were s.c. injected with lectins or vehicle
(TBS-Ca2þ buffer); two hours later, animals were injected (s.c.) with
pathogenic PF IgG (0.4mg g1 body weight). Twenty hours after IgG
injection, the extent of skin disease was evaluated and scored on a
scale of 0 to 3þ as described previously (Li et al., 2005).
Statistical analysis
Data were presented as mean±SD. The Student’s t-test (unpaired,
two-tailed) was used to evaluate for statistical significance. Po0.05
was considered significant.
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